Viatris Inc. (VTRS) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Canonsburg, PA, United States. Le PDG actuel est Scott Andrew Smith.
VTRS a date d'introduction en bourse 1980-03-17, 32,000 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $16.02B.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania, that develops and distributes a diverse portfolio of prescription brand drugs, generic medications, complex generics, biosimilars, and active pharmaceutical ingredients across four geographic segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company operates across multiple therapeutic areas including noncommunicable and infectious diseases, oncology, immunology, endocrinology, and ophthalmology, offering medicines in various formats such as oral solids, injectables, and complex dosage forms. Viatris markets well-known pharmaceutical brands including Lyrica, Lipitor, EpiPen, Viagra, and Celebrex, along with biosimilar franchises such as Fulphila and SEMGLEE, distributing its products through a broad network of pharmaceutical wholesalers, retailers, specialty pharmacies, and e-commerce channels. Beyond medications, the company provides patient support services including diagnostic clinics, educational seminars, and digital health tools. The company maintains strategic partnerships with leading biotechnology firms to expand its innovative pipeline and global reach.
